The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research experts from the charitable, academic and private sectors to expedite development of new drugs for dementia. 11 December 2013
A Twitter debate was sparked yesterday after the Financial Times Global Pharmaceutical & Biotechnology Conference questioned its audience about the gaps in the industry’s skills base. 4 December 2013
The US trade group Biotechnology Industry Organization (BIO) has expressed grave concerns relating to the Innovation Act (HR 3309), which this week gained a strong bipartisan vote from the House Judiciary Committee. 4 December 2013
Most patients don’t appreciate the pharma companies that save their lives, Bayer chairman Marijn Dekkers told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
The Grattan Institute has published an updated report on Australia's drug pricing, which has been applauded by Health Minister Peter Dutton, but not by the generics sector. 3 December 2013
The Indian government has decided that there will be no change in its policy on foreign direct investment (FDI) in the pharmaceutical industry. 2 December 2013
Trade body Medicines Australia has submitted a report to the National Commission of Audit which shows that the key issue for the country’s Pharmaceutical Benefits Scheme (PBS) is ensuring it is fit for purpose for listing new medicines. 2 December 2013
In Greece, the situation in the pharmaceutical sector has reached a full dead-end due to the constant decreases in the pharmaceutical budget, which are effected via segmental, horizontal and unfair collection measures and not via the necessary structural changes. 30 November 2013
Despite objections of the major opposition Coalition of the Radical Left (SYRIZA) party that critics said wanted to protect profits for big pharmaceutical companies who provide it financial support, the Greek Parliament has approved cuts in the prices of state-subsidized medicines, according to the Greek Reporter. 29 November 2013
Members of the generic drugs industry are calling on the Australian government to support efforts to protect access to medicines in negotiations on the Trans Pacific Partnership Agreement (TPPA). 26 November 2013
An aging population will make demands on Australian government budgets at the same time as the country is facing a slowdown in growth and productivity, a new report has warned. 22 November 2013
The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested drugs with horrible side-effects, and there is a desperate need to put pressure on governments and the pharmaceutical industry to increase investment in better TB diagnostics and newer, better TB drugs, says the South Africa-based Treatment Action Group (TAC) in a web site posting. 21 November 2013
New Zealand’s National Party Government’s call for feedback to resolve problems around the tax deductibility of R&D expenditure for businesses is more tinkering and shows a government out of touch with the needs of business, says the Labour Party’s Innovation, Research & Development spokesperson Megan Woods and Revenue spokesperson David Clark. 9 November 2013
The AusBiotech 2013 national conference culminated last week in the signing of a memorandum of understanding (MOU) between the respective trade groups AusBiotech and the Korea Biotechnology Industry Organization (KoreaBIO). 8 November 2013
South Africa’s government’s policy on intellectual property (IP), which is currently under discussion, would seek to strike a balance between the needs of public health and the interests of innovative pharmaceutical companies, Trade and Industry Minister Rob Davies revealed this week. 6 November 2013
The UK government and pharmaceutical companies this morning announced a new five-year, multi-billion pricing deal that will introduce a fixed limit on National Health Service (NHS) spend on branded medicines for the first time ever with all additional expenditure above this level paid for by industry. 6 November 2013
The Australian Federal Minister for Health, Peter Dutton, has announced that the cost of 50 new and amended drugs will be subsidized by the government through its Pharmaceutical Benefits Scheme (PBS). 30 October 2013
Humanitarian medical organization Medecins Sans Frontieres is calling for four key policy changes to reduce the number of children missing out on vaccinations globally from 22.6 million in 2012. 29 October 2013
Canada’s Research-Based Pharmaceutical Companies (Rx&D) association applauds the government of Canada’s announcement regarding the successful conclusion of negotiations surrounding the Comprehensive Economic and Trade Agreement (CETA). 25 October 2013
The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024